Article info
PDFLetter
IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease
- Correspondence to Dr L Naumann, Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany; lydia.naumann{at}charite.de
Citation
IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease
Publication history
- Accepted April 21, 2009
- First published January 26, 2010.
Online issue publication
November 01, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved.